Istodax


Indications and Reactions:

Role Indications Reactions
Primary
Peripheral T-cell Lymphoma Unspecified 26.6%
Product Used For Unknown Indication 22.6%
Mycosis Fungoides 10.6%
T-cell Lymphoma 8.8%
Drug Use For Unknown Indication 5.6%
Lymphoma 5.3%
Non-hodgkin's Lymphoma 4.0%
Anaplastic Large Cell Lymphoma T- And Null-cell Types 2.9%
Hypertension 1.9%
Prophylaxis 1.9%
Multiple Myeloma 1.6%
Infection Prophylaxis 1.3%
Cardiac Disorder 1.1%
Pain 1.1%
Respiratory Failure 1.1%
Depression 0.8%
Nausea 0.8%
Pain Management 0.8%
Pruritus 0.8%
Benign Prostatic Hyperplasia 0.5%
Death 14.8%
Vomiting 9.1%
Infusion Site Extravasation 6.8%
Myocardial Infarction 6.8%
Thrombocytopenia 6.8%
Nausea 5.7%
Pyrexia 5.7%
Drug Ineffective 3.4%
Fatigue 3.4%
General Physical Health Deterioration 3.4%
Haemolytic Anaemia 3.4%
Injection Site Extravasation 3.4%
Neutrophil Count Decreased 3.4%
Peripheral Sensory Neuropathy 3.4%
Platelet Count Decreased 3.4%
Pulmonary Oedema 3.4%
Rash 3.4%
Splenomegaly 3.4%
T-cell Lymphoma 3.4%
Thrombosis 3.4%
Secondary
Mycosis Fungoides 18.6%
Lymphoma 14.7%
Peripheral T-cell Lymphoma Unspecified 11.8%
Anaplastic Large Cell Lymphoma T- And Null-cell Types 10.8%
Cardiac Disorder 7.8%
Multiple Myeloma 5.9%
Product Used For Unknown Indication 5.9%
Electrolyte Substitution Therapy 3.9%
Respiratory Failure 3.9%
T-cell Lymphoma 3.9%
Antiemetic Supportive Care 2.0%
Benign Prostatic Hyperplasia 2.0%
Sepsis 2.0%
Cellulitis 1.0%
Cll 1.0%
Depression 1.0%
Gastritis Prophylaxis 1.0%
Hypertension 1.0%
Hyperuricaemia 1.0%
Insomnia 1.0%
Thrombocytopenia 14.7%
Pyrexia 8.8%
Splenomegaly 8.8%
Diplegia 5.9%
Electrocardiogram Qt Interval Abnormal 5.9%
Monoplegia 5.9%
Pancytopenia 5.9%
White Blood Cell Count Decreased 5.9%
Wound Infection 5.9%
Anaemia 2.9%
Atrial Fibrillation 2.9%
Decreased Appetite 2.9%
General Physical Health Deterioration 2.9%
Hypersensitivity 2.9%
Jugular Vein Thrombosis 2.9%
Multiple Myeloma 2.9%
Myocardial Infarction 2.9%
Pneumonia 2.9%
Restlessness 2.9%
Sepsis 2.9%

Drug Data